			2022 EFPIA DIS	CLOSURE (inc. Vac	ccines Europe)						
				Date of publication:	• ′						
Full Name		Country of Principal Practice	Principal Practice Address	Unique country identifier <i>OPTIONAL</i>		Contribution to costs of Events			Fee for service and consultancy		
	registered				Donations and Grants to HCOs and POs	HCOs POs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the	
			year for an individual HCP will be summed up: i				authorities' consulto	tion only, as appropri		<u> </u>	
emsner	Tübingen	Germany	Universitätsklinikum Tübingen, Postfach 2669, 72016 Tübingen, Deutschland		N/A	N/A			12.000,00€		Comment *
n Mordmueller	Nijmegen	Netherlands	Radboudumc Geert Grooteplein Zuid 10 6525 GA Niimegen		N/A	N/A			12.000,00€		Comment *
Jozwiak	Warschau	Poland	Warschau Universität, Krakowskie Predmiescie 26/28, 00-927 Warschau, Polen		N/A	N/A			8.750,00 €		Comment *
olländer	Basel	Schweiz	Botnar Research Centre for Child Health (BRCCH) Üniversität Basel, Petersgraben 31, 4051 Basel, Schweiz		N/A	N/A		11.026 €	45.984,00 €		Comment *
			14031 Basel Stilwell		N/A	N/A					
			OTHER, NOT INCLUDED ABOVE - where i	information cannot be d	liclsoed on an individu	al basis for legal reaso	ons				
Aggregate amount attributable to transfers of value to such Recipients						N/A					
Number of Recipients in aggregate disclosure % of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed						N/A N/A					
INDIVIDUAL NAMED DISCLOSURE - one l			year for an individual HCO will be summed up: i	itemization should be ave	ailable for the individu	al Recipient or public a	uthorities' consultatio	on only, as appropriate	2)	_	
ildren's Hospital Basel (UKBB), Spitalstrass	e 33, CH-4031, Basel, Schw	reiz							15.303,00€		Comment *
					1			1	+	+	
											İ
			OTHER, NOT INCLUDED ABOVE - where i	information cannot be d			ns				
Aggregate amount attributable to transfers of value to such Recipients					N/A	N/A					
imber of Recipients in aggregate disclosure  of the number of Recipients included in the aggreate disclosure in the total number, by category, of Recipients disclosed					N/A N/A	N/A N/A			1		
Name		Description	of the transfer of value		1	•				'	
INDIVIDUAL NAMED DISCLOSURE - or	ne line per PO (i.e. all tran	nsfers of value during	a year for an individual PO will be summed up: ii	temization should be avo	ailable for the individu	al Recipient or public a	uthorities' consultatio	n only, as appropriate	?)	I	
			OTHER, NOT INCLUDED ABOVE - where i	information cannot be d	diclsoed on an individu	al hasis for legal reaso	nns .				
nount attributable to transfers of value to	such Recipients		WHERE I		N/A	N/A		T	T	1	
Number of Recipients in aggregate disclosure						N/A					
ber of Recipients included in the aggreate	e disclosure in the total nu	mber, by category, o	f Recipients disclosed		N/A	N/A					
				AGGREGATE DISCLOS	SURE		_		_		_
			Transfers of Value to Bose								
d to R&D		1,225,00 €	1.225.00 €	Transfers of Value re Rese		AGGREGATE DISCLOSURE  Transfers of Value re Research & Development as defined  1.225.00 €	Transfers of Value re Research & Development as defined	Transfers of Value re Research & Development as defined	Transfers of Value re Research & Development as defined	Transfers of Value re Research & Development as defined	Transfers of Value re Research & Development as defined

<sup>\*</sup> These Transfer of Values were done by Nobelpharma Co. Ltd. Japan